{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T06:32:21Z","timestamp":1793082741037,"version":"4.5.0"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001843","name":"Science and Engineering Research Board","doi-asserted-by":"publisher","award":["CRG \/2021\/005484"],"award-info":[{"award-number":["CRG \/2021\/005484"]}],"id":[{"id":"10.13039\/501100001843","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.ejphar.2026.179424","type":"journal-article","created":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T23:41:27Z","timestamp":1791848487000},"page":"179424","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Survivin mRNA-lipid nanoparticles promote activation of CD8+Granzyme B+ T cells and effector memory formation for effective oral cancer immunotherapy"],"prefix":"10.1016","volume":"1037","author":[{"given":"Vandana","family":"Krishna","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venkata Vamsi Krishna","family":"Venuganti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.ejphar.2026.179424_bib1","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1200\/JCO.22.00996","article-title":"Phase IIa study of SurVaxM plus adjuvant temozolomide for newly diagnosed glioblastoma","volume":"41","author":"Ahluwalia","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.ejphar.2026.179424_bib39","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.1016\/j.immuni.2021.11.001","article-title":"Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responses","volume":"54","author":"Alameh","year":"2021","journal-title":"Immunity"},{"issue":"3","key":"10.1016\/j.ejphar.2026.179424_bib2","doi-asserted-by":"crossref","first-page":"644","DOI":"10.3390\/vaccines11030644","article-title":"Survivin (BIRC5) peptide vaccine in the 4T1 Murine mammary tumor model: a potential neoadjuvant T cell immunotherapy for triple negative breast cancer: a preliminary study","volume":"11","author":"Burkholz","year":"2023","journal-title":"Vaccines"},{"key":"10.1016\/j.ejphar.2026.179424_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.oraloncology.2021.105451","article-title":"Overview of oral cavity squamous cell carcinoma: risk factors, mechanisms, and diagnostics","volume":"121","author":"Chamoli","year":"2021","journal-title":"Oral Oncol."},{"key":"10.1016\/j.ejphar.2026.179424_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2021.113914","article-title":"Vaccine delivery systems toward lymph nodes","volume":"179","author":"Ding","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"1","key":"10.1016\/j.ejphar.2026.179424_bib4","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1021\/acs.accounts.1c00544","article-title":"Chemistry of lipid nanoparticles for RNA delivery","volume":"55","author":"Eygeris","year":"2022","journal-title":"Accounts of Chemical Research"},{"issue":"11","key":"10.1016\/j.ejphar.2026.179424_bib5","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1007\/s00262-016-1890-x","article-title":"Clinical study of a survivin long peptide vaccine (SurVaxM) in patients with recurrent malignant glioma","volume":"65","author":"Fenstermaker","year":"2016","journal-title":"Cancer Immunol. Immunother."},{"issue":"7","key":"10.1016\/j.ejphar.2026.179424_bib7","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004159","article-title":"Dendritic cell-mediated cross presentation of tumor-derived peptides is biased against plasma membrane proteins","volume":"10","author":"Fessenden","year":"2022","journal-title":"J. Immunother. Cancer"},{"issue":"22","key":"10.1016\/j.ejphar.2026.179424_bib8","doi-asserted-by":"crossref","first-page":"4575","DOI":"10.1158\/1078-0432.CCR-22-3987","article-title":"Survivin dendritic cell vaccine safely induces immune responses and is associated with durable disease control after autologous transplant in patients with myeloma","volume":"29","author":"Freeman","year":"2023","journal-title":"Clin. Cancer Res."},{"issue":"9","key":"10.1016\/j.ejphar.2026.179424_bib9","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.3390\/biomedicines12092158","article-title":"Revolutionizing cancer treatment: recent advances in immunotherapy","volume":"12","author":"Ghemrawi","year":"2024","journal-title":"Biomedicines"},{"issue":"1","key":"10.1016\/j.ejphar.2026.179424_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40580-023-00385-3","article-title":"Lipid nanoparticle-based mRNA delivery systems for cancer immunotherapy","volume":"10","author":"Han","year":"2023","journal-title":"Nano Converg."},{"issue":"1","key":"10.1016\/j.ejphar.2026.179424_bib11","first-page":"87","article-title":"Chemotherapy for oral cancer","volume":"62","author":"Hartner","year":"2018","journal-title":"Dent. Clin."},{"issue":"3","key":"10.1016\/j.ejphar.2026.179424_bib41","doi-asserted-by":"crossref","DOI":"10.1002\/smo.20240067","article-title":"Microneedle delivery systems for vaccines and immunotherapy","volume":"3","author":"Jia","year":"2025","journal-title":"Smart Molecules"},{"issue":"7607","key":"10.1016\/j.ejphar.2026.179424_bib12","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/nature18300","article-title":"Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy","volume":"534","author":"Kranz","year":"2016","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.ejphar.2026.179424_bib13","doi-asserted-by":"crossref","DOI":"10.1007\/s12032-026-03349-9","article-title":"Survivin mRNA lipid nanoparticles and CTLA-4 inhibitor co-delivery activates anti-tumor cytotoxic T-lymphocytes for oral cancer immunotherapy","volume":"43","author":"Krishna","year":"2026","journal-title":"Medical oncology (Northwood, London, England)"},{"issue":"11","key":"10.1016\/j.ejphar.2026.179424_bib14","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.2217\/imt.13.120","article-title":"Dendritic cell vaccines targeting survivin in head and neck cancer","volume":"5","author":"Lee","year":"2013","journal-title":"Immunotherapy"},{"issue":"393","key":"10.1016\/j.ejphar.2026.179424_bib44","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aal2094","article-title":"Vaccine priming is restricted to draining lymph nodes and controlled by adjuvant-mediated antigen uptake","volume":"9","author":"Liang","year":"2017","journal-title":"Sci. Transl. Med."},{"issue":"3","key":"10.1016\/j.ejphar.2026.179424_bib40","doi-asserted-by":"crossref","DOI":"10.1002\/smo.20240030","article-title":"Recent progress in stimuli\u2010activable metallo\u2010prodrugs for cancer therapy","volume":"2","author":"Liang","year":"2024","journal-title":"Smart Molecules"},{"issue":"1","key":"10.1016\/j.ejphar.2026.179424_bib15","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ymthe.2017.10.020","article-title":"Combination immunotherapy of MUC1 mRNA Nano-vaccine and CTLA-4 blockade effectively inhibits growth of triple negative breast cancer","volume":"26","author":"Liu","year":"2018","journal-title":"Mol. Ther."},{"issue":"5","key":"10.1016\/j.ejphar.2026.179424_bib16","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1002\/eji.200737984","article-title":"Nanoparticles target distinct dendritic cell populations according to their size","volume":"38","author":"Manolova","year":"2008","journal-title":"Eur. J. Immunol."},{"issue":"1-3","key":"10.1016\/j.ejphar.2026.179424_bib42","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1385\/IR:36:1:127","article-title":"Professional antigen-presenting cells of the skin","volume":"36","author":"Mathers","year":"2006","journal-title":"Immunol. Res."},{"issue":"1","key":"10.1016\/j.ejphar.2026.179424_bib17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/15476286.2024.2333123","article-title":"mRNA vaccine designs for optimal adjuvanticity and delivery","volume":"21","author":"Mochida","year":"2024","journal-title":"RNA Biol."},{"issue":"2","key":"10.1016\/j.ejphar.2026.179424_bib18","doi-asserted-by":"crossref","first-page":"338","DOI":"10.3390\/cancers13020338","article-title":"Recent advances and future directions in clinical management of head and neck squamous cell carcinoma","volume":"13","author":"Muzaffar","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.ejphar.2026.179424_bib19","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.addr.2020.06.003","article-title":"Dawn of lipid nanoparticles in lymph node targeting: potential in cancer immunotherapy","volume":"167","author":"Nakamura","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"12","key":"10.1016\/j.ejphar.2026.179424_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2021.103479","article-title":"The mRNA-LNP platform's lipid nanoparticle component used in preclinical vaccine studies is highly inflammatory","volume":"24","author":"Ndeupen","year":"2021","journal-title":"iScience"},{"key":"10.1016\/j.ejphar.2026.179424_bib20","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.jconrel.2022.06.017","article-title":"On the size-regulation of RNA-loaded lipid nanoparticles synthesized by microfluidic device","volume":"348","author":"Okuda","year":"2022","journal-title":"J. Contr. Release"},{"issue":"8","key":"10.1016\/j.ejphar.2026.179424_bib22","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/j.cell.2023.02.031","article-title":"Delivering the next generation of cancer immunotherapies with RNA","volume":"186","author":"Raimondo","year":"2023","journal-title":"Cell"},{"issue":"10","key":"10.1016\/j.ejphar.2026.179424_bib23","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1038\/nbt1332","article-title":"Exploiting lymphatic transport and complement activation in nanoparticle vaccines","volume":"25","author":"Reddy","year":"2007","journal-title":"Nat. Biotechnol."},{"issue":"6","key":"10.1016\/j.ejphar.2026.179424_bib25","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1038\/sj.bjc.6600133","article-title":"Expression of survivin, a novel inhibitor of apoptosis and cell cycle regulatory protein, in pancreatic adenocarcinoma","volume":"86","author":"Sarela","year":"2002","journal-title":"Br. J. Cancer"},{"issue":"5","key":"10.1016\/j.ejphar.2026.179424_bib26","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1007\/s00262-019-02315-x","article-title":"A phase I\/IIa study of the mRNA-based cancer immunotherapy CV9201 in patients with stage IIIB\/IV non-small cell lung cancer","volume":"68","author":"Sebastian","year":"2019","journal-title":"Cancer Immunol. Immunother."},{"issue":"1","key":"10.1016\/j.ejphar.2026.179424_bib27","first-page":"12","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J. Clin."},{"issue":"1","key":"10.1016\/j.ejphar.2026.179424_bib28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10989-021-10334-5","article-title":"Head and neck squamous cell carcinoma: risk factors, molecular alterations, immunology and peptide vaccines","volume":"28","author":"Sun","year":"2022","journal-title":"Int. J. Pept. Res. Therapeut."},{"key":"10.1016\/j.ejphar.2026.179424_bib29","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.addr.2020.04.002","article-title":"Targeted lipid nanoparticles for RNA therapeutics and immunomodulation in leukocytes","volume":"159","author":"Veiga","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejphar.2026.179424_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.nantod.2019.100766","article-title":"Three decades of messenger RNA vaccine development","volume":"28","author":"Verbeke","year":"2019","journal-title":"Nano Today"},{"issue":"10","key":"10.1016\/j.ejphar.2026.179424_bib32","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.3390\/vaccines12101148","article-title":"Recent advances in lipid nanoparticles and their safety concerns for mRNA delivery","volume":"12","author":"Wang","year":"2024","journal-title":"Vaccines"},{"issue":"7","key":"10.1016\/j.ejphar.2026.179424_bib33","doi-asserted-by":"crossref","DOI":"10.1242\/jcs.223826","article-title":"Survivin at a glance","volume":"132","author":"Wheatley","year":"2019","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.ejphar.2026.179424_bib34","first-page":"S91","volume":"63","author":"Wong","year":"2018","journal-title":"Oral Cancer\u2019, Australian Dental Journal"},{"issue":"3","key":"10.1016\/j.ejphar.2026.179424_bib35","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s11095-021-03015-x","article-title":"Nanoparticle-Mediated cytoplasmic delivery of messenger RNA vaccines: challenges and future perspectives","volume":"38","author":"Wu","year":"2021","journal-title":"Pharm. Res."},{"issue":"1","key":"10.1016\/j.ejphar.2026.179424_bib36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-021-08170-3","article-title":"The prognostic significance of survivin expression in patients with HNSCC: a systematic review and meta-analysis","volume":"21","author":"Zhou","year":"2021","journal-title":"BMC Cancer"},{"issue":"31","key":"10.1016\/j.ejphar.2026.179424_bib37","doi-asserted-by":"crossref","first-page":"6765","DOI":"10.1039\/D0TB00649A","article-title":"Overcoming the biological barriers in the tumor microenvironment for improving drug delivery and efficacy","volume":"8","author":"Zhou","year":"2020","journal-title":"J. Mater. Chem. B"}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299926009064?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299926009064?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T05:32:55Z","timestamp":1793079175000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299926009064"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":40,"alternative-id":["S0014299926009064"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2026.179424","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Survivin mRNA-lipid nanoparticles promote activation of CD8+Granzyme B+ T cells and effector memory formation for effective oral cancer immunotherapy","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2026.179424","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"179424"}}